-
EP3906925
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3906925
| EP3906925 - USE OF FLAP INHIBITORS TO REDUCE NEUROINFLAMMATION MEDIATED INJURY IN THE CENTRAL NERVOUS SYSTEM [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 16.09.2022 Database last updated on 03.01.2025 | |
| Former | The application has been published Status updated on 08.10.2021 | Most recent event Tooltip | 16.09.2022 | Application deemed to be withdrawn | published on 19.10.2022 [2022/42] | Applicant(s) | For all designated states Bioscience Pharma Partners, LLC 6135 East Harvard Street Phoenix, AZ 85257 / US | [2021/45] | Inventor(s) | 01 /
HEIDENREICH, Kim A Denver, 80220 / US | 02 /
MURPHY, Robert C Denver, 80231 / US | [2021/45] | Representative(s) | Rudkin, Mairi Ellen Marks & Clerk LLP The Beacon 176 St Vincent Street Glasgow G2 5SG / GB | [N/P] |
| Former [2021/45] | Rudkin, Mairi Ellen Marks & Clerk LLP Aurora 120 Bothwell Street Glasgow G2 7JS / GB | Application number, filing date | 21166657.3 | 04.02.2015 | [2021/45] | Priority number, date | US201461935763P | 04.02.2014 Original published format: US 201461935763 P | [2021/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3906925 | Date: | 10.11.2021 | Language: | EN | [2021/45] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.10.2021 | Classification | IPC: | A61K31/4709, A61K31/405, A61K31/404, A61K9/00, A61P25/00 | [2021/45] | CPC: |
A61K31/4709 (EP,US);
A61K31/404 (EP,US);
A61K31/405 (EP,US);
A61K45/06 (EP,US);
A61K9/0043 (EP,US);
A61P25/00 (EP)
| C-Set: |
A61K31/404, A61K2300/00 (US,EP);
A61K31/405, A61K2300/00 (US,EP);
A61K31/4709, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/45] | Title | German: | VERWENDUNG VON FLAP-HEMMERN ZUR VERRINGERUNG VON NERVENENTZÜNDUNGSVERMITTELTEN LÄSIONEN DES ZENTRALEN NERVENSYSTEMS | [2021/45] | English: | USE OF FLAP INHIBITORS TO REDUCE NEUROINFLAMMATION MEDIATED INJURY IN THE CENTRAL NERVOUS SYSTEM | [2021/45] | French: | UTILISATION D'INHIBITEURS DE FLAP POUR RÉDUIRE UNE LÉSION MEDIÉE PAR UNE NEURO-INFLAMMATION DANS LE SYSTÈME NERVEUX CENTRAL | [2021/45] | Examination procedure | 11.05.2022 | Application deemed to be withdrawn, date of legal effect [2022/42] | 01.06.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2022/42] | Parent application(s) Tooltip | EP15705756.3 / EP3102209 | Fees paid | Renewal fee | 05.07.2021 | Renewal fee patent year 03 | 05.07.2021 | Renewal fee patent year 04 | 05.07.2021 | Renewal fee patent year 05 | 05.07.2021 | Renewal fee patent year 06 | 05.07.2021 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 28.02.2022 | 08 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO0205825 (BRISTOL MYERS SQUIBB CO [US]) [X] 1-4,6,11-15 * page 1, lines 10-18; claims 7-8, 11-12 * [I] 5,7-10; | [A]US2013090315 (VANLANDINGHAM JACOB W [US], et al) [A] 1-15 * paragraphs [0063] - [0065] *; | [XI]US2013310421 (PRATICO DOMENICO [US]) [X] 1-4,6,10-15 * paragraphs [0010] , [0017] , [0042] - [0044] - [0050] - [0051] - [0078]; example 2; claims 1,2,7,10-13,18-22 * [I] 5,7-9; | [XI] - C. VOIGT ET AL, "Effect of leukotriene inhibitors on evolution of experimental brain contusions", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, (20120511), vol. 38, no. 4, doi:10.1111/j.1365-2990.2011.01211.x, ISSN 0305-1846, pages 354 - 366, XP055187126 [X] 1-6,11-15 * abstract * * page 360, column 2, paragraphs 2-3; figures 3,6 * * page 361, column 1, paragraph 3 - column 2, paragraph 2 * * page 363, column 2, paragraph 4 * [I] 7-10 DOI: http://dx.doi.org/10.1111/j.1365-2990.2011.01211.x | [XI] - HÄRTIG WOLFGANG ET AL, "Impact of 5-lipoxygenase inhibitors on the spatiotemporal distribution of inflammatory cells and neuronal COX-2 expression following experimental traumatic brain injury in rats", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, (20121223), vol. 1498, doi:10.1016/J.BRAINRES.2012.12.022, ISSN 0006-8993, pages 69 - 84, XP028577724 [X] 1-6,11-15 * abstract * * page 81, column 2, paragraph 3.5 * [I] 7-10 DOI: http://dx.doi.org/10.1016/j.brainres.2012.12.022 | [XI] - YOSHIKAWA K ET AL, "Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE, EDINBURGH, vol. 85, no. 1, doi:10.1016/J.PLEFA.2011.04.022, ISSN 0952-3278, (20110412), pages 43 - 52, (20110422), XP028373456 [X] 1-6,11-15 * abstract * * page 46, column 2, paragraph 3 - page 48, column 2, paragraph 2 * [I] 7-10 DOI: http://dx.doi.org/10.1016/j.plefa.2011.04.022 | [XI] - KAI-HSIANG KANG ET AL, "Protection of dopaminergic neurons by 5-lipoxygenase inhibitor", NEUROPHARMACOLOGY, (20131001), vol. 73, doi:10.1016/j.neuropharm.2013.06.014, ISSN 0028-3908, pages 380 - 387, XP055187128 [X] 1-6,11-15 * abstract * [I] 7-10 DOI: http://dx.doi.org/10.1016/j.neuropharm.2013.06.014 | [A] - SANTIAGO FARIAS ET AL, "Injury-Related Production of Cysteinyl Leukotrienes Contributes to Brain Damage following Experimental Traumatic Brain Injury", JOURNAL OF NEUROTRAUMA, (20091101), vol. 26, no. 11, doi:10.1089/neu.2009.0877, ISSN 0897-7151, pages 1977 - 1986, XP055187130 [A] 1-15 * abstract * * page 1984, column 2, paragraph 3; figure 4 * DOI: http://dx.doi.org/10.1089/neu.2009.0877 | [A] - HANSON LEAH R ET AL, "Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease", BMC NEUROSCIENCE, BIOMED CENTRAL, LONDON, GB, (20081210), vol. 9, no. Suppl 3, doi:10.1186/1471-2202-9-S3-S5, ISSN 1471-2202, page S5, XP021042511 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1186/1471-2202-9-S3-S5 | [XP] - CHELSEA E. CORSER-JENSEN ET AL, "Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits", EXPERIMENTAL NEUROLOGY, (20140601), vol. 256, doi:10.1016/j.expneurol.2014.03.008, ISSN 0014-4886, pages 7 - 16, XP055187111 [XP] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.expneurol.2014.03.008 | by applicant | - MURPHY RC et al., Proc Natl Acad Sci USA, (19790000), vol. 76, pages 4275 - 4279 | - FOLCO, GMURPHY RC, Pharmacol. Rev., (20060000), vol. 58, pages 375 - 388 | - BOYCE JA, Immunol. Rev., (20070000), vol. 217, pages 168 - 185 | - FARIAS S et al., J. Neurotraum., (20090000), vol. 26, pages 1977 - 1986 | - FARIAS et al., J. Neurochem., (20070000), vol. 103, pages 1310 - 1318 | - B. S. FRIEDMANE. H. BELA. BUNTINXW. TANAKAY. H. HANS. SHINGOR. SPECTORP. STERK, "Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses", Am. Rev. Respir. Dis., (19930000), vol. 147, pages 839 - 844, XP008113657 | - B. DAHLENM. KUMLINE. IHREO. ZETTERSTROMS. E. DAHLEN, "Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005", Thorax, (19970000), vol. 52, pages 342 - 347 | - Z. DIAMANTM. C. TIMMERSH. VAN DER VEENB. S. FRIEDMANM. DE SMETM. DEPRED. HILLIARDE. H. BELP. J. STERK, "The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo", J. Allergy Clin. Immun., (19950000), vol. 95, doi:10.1016/S0091-6749(95)70151-6, pages 42 - 51, XP005111493 DOI: http://dx.doi.org/10.1016/S0091-6749(95)70151-6 | - FREY L.C. et al., J. Neurosci. Methods, (20090000), vol. 177, pages 267 - 272 | - UYAMA O, J. Cerebr. Blood F. Met., (19880000), vol. 8, pages 282 - 284 | - HANSON LR et al., Drug Delivery, (20120000), vol. 19, no. 3, pages 149 - 54 |